Insights Into Abdominal Wall Vascularized Composite Allotransplantation: An Individual Patient Data Analysis

ABSTRACT Background Abdominal wall vascularized composite allotransplantation (AWT) has emerged as a reconstructive option for patients with complex abdominal wall defects, particularly in conjunction with intestinal transplantation. Despite more than 2 decades of clinical experience, the available evidence remains limited to isolated case reports and small case series, and important questions regarding patient selection, operative techniques, immunosuppressive strategies, rejection patterns, and clinical outcomes remain unanswered. Therefore, we performed an individual patient data analysis to comprehensively evaluate the current evidence and provide insights into the clinical applicability, efficacy, and limitations of AWT. Methods We conducted a systematic review with an individual patient data analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. PubMed, Web of Science, Scopus, and Embase were searched through December 2025. Results Twenty studies published between 2003 and 2023 reported 35 individual patients who underwent 37 AWT procedures. The median patient age was 37.5 years (IQR, 17.9), and follow‐up ranged from 1 to 7 years. Alemtuzumab was used for induction in 32 patients (91.4%). The principal indications were large abdominal wall defects in 17 patients (48.6%), malignancy in 11 (31.4%), motility disorders in three (8.6%), and vascular disorders and congenital defects in two patients each (5.7%). All AWT procedures were performed in conjunction with intestinal transplantation; 23 patients (65.7%) received isolated intestinal transplantation and 12 (34.3%) received multivisceral transplantation. Thirteen patients (37.2%) developed biopsy‐proven AWT rejection. None of the assessed factors was significantly associated with rejection (all p > 0.05). Conclusion AWT is a feasible reconstructive option for selected patients with extensive abdominal wall defects undergoing intestinal or multivisceral transplantation. However, the limited number of patients and heterogeneous outcome reporting precludes firm conclusions regarding long‐term functional durability and predictors of rejection.

Authors

Institutions

Publication Details

Journal
Microsurgery
Published
2026-11-14
DOI
https://doi.org/10.1002/micr.70346
Primary Topic
Organ and Tissue Transplantation Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Insights Into Abdominal Wall Vascularized Composite Allotransplantation: An Individual Patient Data Analysis

Arianeb Mehrabi, Elias Khajeh, Christoph Koepple, Christoph Michalski et al.
Microsurgery
Organ and Tissue Transplantation Research
article

Insights Into Abdominal Wall Vascularized Composite Allotransplantation: An Individual Patient Data Analysis

Arianeb Mehrabi, Elias Khajeh, Christoph Koepple, Christoph Michalski, Nastaran Sabetkish, Mohammadamin Shahrbaf, Ulrich Kneser, Mohammadsadegh Sabagh
article en

Abstract

ABSTRACT Background Abdominal wall vascularized composite allotransplantation (AWT) has emerged as a reconstructive option for patients with complex abdominal wall defects, particularly in conjunction with intestinal transplantation. Despite more than 2 decades of clinical experience, the available evidence remains limited to isolated case reports and small case series, and important questions regarding patient selection, operative techniques, immunosuppressive strategies, rejection patterns, and clinical outcomes remain unanswered. Therefore, we performed an individual patient data analysis to comprehensively evaluate the current evidence and provide insights into the clinical applicability, efficacy, and limitations of AWT. Methods We conducted a systematic review with an individual patient data analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) statement. PubMed, Web of Science, Scopus, and Embase were searched through December 2025. Results Twenty studies published between 2003 and 2023 reported 35 individual patients who underwent 37 AWT procedures. The median patient age was 37.5 years (IQR, 17.9), and follow‐up ranged from 1 to 7 years. Alemtuzumab was used for induction in 32 patients (91.4%). The principal indications were large abdominal wall defects in 17 patients (48.6%), malignancy in 11 (31.4%), motility disorders in three (8.6%), and vascular disorders and congenital defects in two patients each (5.7%). All AWT procedures were performed in conjunction with intestinal transplantation; 23 patients (65.7%) received isolated intestinal transplantation and 12 (34.3%) received multivisceral transplantation. Thirteen patients (37.2%) developed biopsy‐proven AWT rejection. None of the assessed factors was significantly associated with rejection (all p > 0.05). Conclusion AWT is a feasible reconstructive option for selected patients with extensive abdominal wall defects undergoing intestinal or multivisceral transplantation. However, the limited number of patients and heterogeneous outcome reporting precludes firm conclusions regarding long‐term functional durability and predictors of rejection.

MicrosurgeryVol. 46(8)
Heidelberg University (DE), University Hospital Heidelberg (DE), Berufsgenossenschaftliche Unfallklinik Ludwigshafen (DE), Chirurgische Universitätsklinik Heidelberg (DE)
Organ and Tissue Transplantation Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon